Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo by Smith, Jesse J et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
BMC Systems Biology
Open Access Research article
Small molecule activators of SIRT1 replicate signaling pathways 
triggered by calorie restriction in vivo
Jesse J Smith†1, Renée Deehan Kenney†2, David J Gagne1, Brian P Frushour2, 
William Ladd2, Heidi L Galonek1, Kristine Israelian1, Jeffrey Song1, 
Giedre Razvadauskaite1, Amy V Lynch1, David P Carney1, Robin J Johnson2, 
Siva Lavu1, Andre Iffland1, Peter J Elliott1, Philip D Lambert1, 
Keith O Elliston2, Michael R Jirousek1, Jill C Milne1 and Olivier Boss*†1
Address: 1Sirtris, a GSK company 200 Technology Square, Cambridge, MA, 02139, USA and 2Genstruct Inc, One Alewife Center, Cambridge, MA, 
02140, USA
Email: Jesse J Smith - jessejersmith@gmail.com; Renée Deehan Kenney - rkenney@genstruct.com; David J Gagne - dgagne@sirtrispharma.com; 
Brian P Frushour - bfrushour@genstruct.com; William Ladd - ladd@genstruct.com; Heidi L Galonek - hgalonek@sirtrispharma.com; 
Kristine Israelian - kisraelian@sirtrispharma.com; Jeffrey Song - jsong@sirtrispharma.com; Giedre Razvadauskaite - nelia0505@yahoo.com; 
Amy V Lynch - alynch@sirtrispharma.com; David P Carney - dcarney@sirtrispharma.com; Robin J Johnson - rjohnson@genstruct.com; 
Siva Lavu - slavu@sirtrispharma.com; Andre Iffland - aiffland@sirtrispharma.com; Peter J Elliott - pelliott@sirtrispharma.com; 
Philip D Lambert - plambert@sirtrispharma.com; Keith O Elliston - kelliston@genstruct.com; Michael R Jirousek - mjirousek@msn.com; 
Jill C Milne - jillcmilne@yahoo.com; Olivier Boss* - oboss@sirtrispharma.com
* Corresponding author    †Equal contributors
Abstract
Background: Calorie restriction (CR) produces a number of health benefits and ameliorates diseases of
aging such as type 2 diabetes. The components of the pathways downstream of CR may provide
intervention points for developing therapeutics for treating diseases of aging. The NAD+-dependent
protein deacetylase SIRT1 has been implicated as one of the key downstream regulators of CR in yeast,
rodents, and humans. Small molecule activators of SIRT1 have been identified that exhibit efficacy in animal
models of diseases typically associated with aging including type 2 diabetes. To identify molecular processes
induced in the liver of mice treated with two structurally distinct SIRT1 activators, SIRT501 (formulated
resveratrol) and SRT1720, for three days, we utilized a systems biology approach and applied Causal
Network Modeling (CNM) on gene expression data to elucidate downstream effects of SIRT1 activation.
Results:  Here we demonstrate that SIRT1 activators recapitulate many of the molecular events
downstream of CR in vivo, such as enhancing mitochondrial biogenesis, improving metabolic signaling
pathways, and blunting pro-inflammatory pathways in mice fed a high fat, high calorie diet.
Conclusion: CNM of gene expression data from mice treated with SRT501 or SRT1720 in combination
with supporting in vitro and in vivo data demonstrates that SRT501 and SRT1720 produce a signaling profile
that mirrors CR, improves glucose and insulin homeostasis, and acts via SIRT1 activation in vivo. Taken
together these results are encouraging regarding the use of small molecule activators of SIRT1 for
therapeutic intervention into type 2 diabetes, a strategy which is currently being investigated in multiple
clinical trials.
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Background
Calorie restriction (CR), defined as a reduction of caloric
intake with adequate nutrition, ameliorates common dis-
eases of aging, such as insulin resistance, type 2 diabetes
mellitus (T2DM), dyslipidemia, neurodegenerative disor-
ders and cancer [1-5]. CR is effective in extending lifespan
in most every organism examined to date, including yeast,
drosophila, and several mammalian species [4,6-8]. The
mechanism underlying these beneficial effects is not well
understood and elucidation of the molecular signaling
pathways downstream of CR might enable pharmacolog-
ical intervention into this pathway [9,10].
Silent information regulator 2 (SIR2) was first identified
as a mediator of CR-induced lifespan extension in yeast
[11]and subsequently has been shown to regulate this
process in lower metazoans, such as Drosophila mela-
nogaster and C. elegans [12-14]. The mammalian ortholog
of Sir2, SIRT1, is an NAD+-dependent protein deacetylase
that catalyzes the removal of acetyl groups from lysine res-
idues in substrate proteins. SIRT1 deacetylates a number
of cellular proteins including p53, FOXO, PGC-1α, and
LXR [15-22]. Following a regimen of CR in both rodents
and in humans, SIRT1 expression levels are increased [23-
26]. SIRT1 belongs to the sirtuin family that consists of
seven enzymes that share a conserved core catalytic
domain but differ in their flanking amino- and carboxy-
terminal sequences, cellular localization, tissue distribu-
tion, and substrate proteins [27-29]. Increasing evidence
implicates mammalian sirtuins as regulators of CR-
induced physiological responses, including lipid metabo-
lism, glucose homeostasis, stress responses and insulin
secretion [29].
As potential mediators of CR in vivo, the sirtuin enzymes
may represent novel intervention points for developing
therapeutics to treat diseases of aging such as type 2 diabe-
tes. In particular, SIRT1 activators have been described
and these show promise in improving metabolic profiles
in both genetic and diet induced obese rodents. The first
SIRT1 activator described, resveratrol, is a polyphenolic
compound found in red wine. Resveratrol is a micromolar
activator of SIRT1 in vitro and has been shown to improve
the metabolic profile of mice fed a high fat diet [30,31]. In
this model of type 2 diabetes resveratrol increases mito-
chondrial biogenesis and ameliorates insulin resistance.
Recently, we reported novel small molecule activators of
SIRT1 that are 1000 times more potent than resveratrol
[32]. These compounds are structurally distinct from res-
veratrol but act through the same enzymatic mechanism,
binding to an allosteric site exposed in the enzyme-sub-
strate complex and thereby lowering the Km of SIRT1 for
its acetylated peptide substrates. Most notably, these mol-
ecules exhibit good oral bioavailability in rodents and like
resveratrol, improve both glucose and insulin homeosta-
sis in ob/ob mice, diet induced obese mice, and Zucker fa/
fa rats.
In this report we characterize the early molecular signaling
events that are shared between treatment with two struc-
turally distinct SIRT1 activating compounds, SRT501, a
proprietary formulation of resveratrol with enhanced
pharmacokinetic properties and improved oral bioavaila-
bility, and SRT1720, a chemically distinct compound with
nanomolar potency toward SIRT1 [32]. Using a Causal
Network Modeling (CNM) approach empowered by tran-
scriptional profiling data from mice treated with the
SIRT1 activators and a global knowledgebase, we deter-
mined that SRT501 and SRT1720 recapitulate a molecular
signature which overlaps with that of CR. Furthermore, we
characterize several key hypotheses underlying the CR net-
work for SIRT1 activator mechanism of action, and show
that metabolism mediated by Ppar family members is
upregulated, mitochondrial biogenesis is enhanced, and
pro-inflammatory signaling is decreased. In addition,
both SRT501 and SRT1720 show significant overlap in the
signaling pathways they modulate supporting the concept
that these structurally distinct compounds act on the same
molecular target, SIRT1, in vivo. Finally, we provide com-
plementary in vivo and in vitro evidence that supports the
hypothesis that SIRT1 activation in vivo by small mole-
cules mimics calorie restriction.
Results
Small molecule activators of SIRT1 improve metabolic
parameters in several rodent models of T2DM. To eluci-
date the pathways downstream of SIRT1 activation
responsible for the observed efficacy in these in vivo mod-
els, we performed Causal Network Modeling (CNM) of
gene expression data from livers of mice fed a high fat diet
(diet-induced obesity, DIO) and treated with SIRT1 acti-
vators, SRT501 (1000 mg/kg, oral dosing) or SRT1720
(100 mg/kg, oral dosing) for three days (Figure 1). Both
compounds exhibit good oral bioavailability in mice.
Chemical Structures of SRT501-resveratrol and SRT1720 Figure 1
Chemical Structures of SRT501-resveratrol and 
SRT1720.BMC Systems Biology 2009, 3:31 http://www.biomedcentral.com/1752-0509/3/31
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CNM utilizes a species-specific knowledge assembly
model derived from a global knowledgebase (see Addi-
tional file 1) as the substrate for automated reverse causal
analysis powered by gene expression changes (state
changes) from the experiment under analysis (see Materi-
als and Methods for more information)[33,34]. Auto-
mated reverse causal analysis generates a list of statistically
significant upstream explanations, or hypotheses, for
changes in RNA expression in response to SIRT1 activator
treatment. These hypotheses are subsequently evaluated
for biological integrity and experimental relevance and
assembled into causal biological networks. Automated
reverse causal analysis identified 146 statistically signifi-
cant hypotheses that could explain the changes in gene
expression observed in the livers of DIO mice treated with
SRT501 for 3 days versus controls (SRT501 dataset com-
parison). Three key pathways, comprised of 12 of the 146
hypotheses are the focus of this report: 1) calorie restric-
tion-resveratrol treatment, 2) increased metabolism and
mitochondrial biogenesis and 3) decreased pro-inflam-
matory signaling. These pathways were chosen because to
date, they have been validated by in vitro and in vivo exper-
imental data. Initially, we characterized the molecular
pathways induced by SRT501 and in order to determine if
the mechanisms identified for SRT501 treatment were
congruous with SRT1720 treatment, the directionality of
the individual expression changes supporting the hypoth-
eses identified from SRT501 treatment were compared to
those observed after SRT1720 treatment using a statistical
comparison at the probe set level. Finally, the results of
our modeling efforts were confirmed by in vitro and in vivo
experimental data.
Statistical analysis of the microarray data identified 342
genes whose RNA expression was significantly modulated
in response to SRT501 treatment. While all molecular
state changes can be mapped to the knowledgebase, only
the subset of these changes that have one or more
upstream causal assertions in the knowledgebase are con-
sidered causally modeled. If there is no information in the
knowledgebase for the transcriptional control of a given
gene, then it is not possible to identify hypotheses that
can explain this state change. In the case of the SRT501
dataset, 78% (266 of 342) of the state changes were caus-
ally modeled. The high percentage of modeled state
changes indicates that the knowledgebase is sufficiently
enriched with causal information about the experimental
outcome to be competent for reverse causal analysis.
SRT501 and SRT1720 generate a gene expression profile 
similar to that of calorie restriction
One of the strongest hypotheses generated from reverse
causal analysis on the SRT501 dataset comparison is CR,
supported by 54 independent changes in gene expression,
corresponding to ~20% of the causally modeled state
changes (Figure 2[a] and 2[b]). Reverse causal analysis on
the SRT501 dataset comparison identified two processes
downstream from SRT501 treatment that are supported
by causal networks of statistically significant hypotheses:
the increased metabolism and mitochondrial biogenesis
network and the decreased inflammation network (Figure
2[a]). Together, these two networks along with the CR and
resveratrol treatment hypotheses (discussed below) make
up the larger CR network for SIRT1 activator mechanism
of action. To determine whether the CR hypothesis was
also supported in the SRT1720 dataset comparison, we
analyzed the 73 probe sets mapping to the 54 state
changes underlying the CR hypothesis. Importantly, all 73
probe sets were modulated in the same direction in the
SRT1720 and SRT501 dataset comparisons (p < 10-5, Fig-
ure 2[c]) suggesting that these two structurally distinct
SIRT1 activators act via the same mechanism in vivo. These
findings support the hypothesis that SRT1720, like
SRT501, induces a gene expression profile similar to CR.
Notably, resveratrol treatment was identified as a statisti-
cally significant hypothesis supported by 62 state changes
(~23% of the causally modeled state changes). The resver-
atrol treatment hypothesis is supported by data encoded
into the knowledgebase from prior studies demonstrating
that this compound recapitulates many of the metabolic
benefits of CR in rodent models of obesity and insulin
resistance [30,31]. As with the CR hypothesis, analysis of
the state changes underlying the resveratrol treatment
hypothesis determined that probe sets mapping to these
state changes were modulated in the same direction after
SRT1720 treatment compared to SRT501 treatment (p <
10-5, see Additional file 2).
In vivo efficacy data for SRT501 and SRT1720 in multiple
rodent models for T2DM also agree with the CR network
shown in Figure 2[a], where these compounds exhibit
similar effects to calorie restriction. We recently reported
that these SIRT1 activators, like calorie restriction,
improve glucose and insulin homeostasis in three models
of T2DM: a C57BL/6 mouse diet-induced-obesity model,
an ob/ob mouse model and a Zucker fa/fa model [32]. Fig-
ure 2[d] demonstrates efficacy of these two compounds in
the diet-induced obesity model using C57BL/6 mice. After
3 weeks of dosing mice with SRT501 (1000 mg/kg) and
SRT1720 (100 mg/kg), fasted blood glucose is decreased
by 24% and 20% in SRT501 and SRT1720 treatment
groups respectively compared to vehicle control animals.
Similarly, fed insulin levels are decreased by ~60% and
~50% respectively in animals dosed with SRT501 (1000
mg/kg) or SRT1720 (100 mg/kg) compared to vehicle
control animals. These data are consistent with our previ-
ously reported findings that SRT501 and SRT1720
improve glucose and insulin homeostasis in rodent mod-
els of T2DM [32].BMC Systems Biology 2009, 3:31 http://www.biomedcentral.com/1752-0509/3/31
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SRT501 and SRT1720 increase metabolic signaling and 
mitochondrial biogenesis
The hypotheses supporting the increased metabolism and
mitochondrial biogenesis network downstream of
SRT501 treatment are displayed in Figure 3[a]. One key
hypothesis supporting this process is increased transcrip-
tional activity of Ppargc1α (Pgc-1α) which is supported by
6 state changes. Several reports have demonstrated that
deacetylation of Ppargc1α by SIRT1 at multiple lysine res-
idues leads to increased transcriptional activity of
Ppargc1α towards its target genes (Rodgers et al 2005).
Furthermore, Ppargc1α is known to function as a coacti-
vator for nuclear hormone receptors, such as Ppar α,γ,δ
and Esrrα (Errα), all of which are predicted to have
SRT1720 behaves as a mimetic for calorie restriction and improves glucose homeostasis and insulin sensitivity Figure 2
SRT1720 behaves as a mimetic for calorie restriction and improves glucose homeostasis and insulin sensitivity. 
[a] Flow diagram depicting the downstream effects of Sirt1 activation by the compounds SRT501 and SRT1720 in DIO mouse 
livers after 3 days of treatment. Green – measured and observed increase. Yellow – statistically significant hypothesized 
increase. White – a given process (e.g. inflammation) supported by statistically significant hypotheses. Blue – hypothesized 
decrease in activity or abundance. Non-directional lines indicate similarity between SRT501, SRT1720 and resveratrol treat-
ment and the effects of calorie restriction. Lines with arrowheads indicate causal activation; lines with bars indicate causal inhi-
bition. The direction of the arrow in boxes indicates whether a process, hypothesis or observation shows an increase or 
decrease with SRT501 or SRT1720. Numbers in brackets indicate the number of RNA state changes supporting that hypothe-
sis. [b] Table of processes activated or attenuated in response to SRT501 and SRT1720 treatment and the statistically signifi-
cant hypotheses that support them. [c] Scatter plot obtained by graphing fold changes of significant probe sets supporting the 
increased CR hypothesis in the SRT1720 dataset comparison versus the SRT501 dataset comparison. [d] Fasted plasma glucose 
levels were improved following treatment with either SRT501 (1000 mg/kg) or SRT1720 (100 mg/kg) as compared to vehicle 
treated DIO mice (* p < 0.05). Fed plasma insulin following treatment with SRT501 (1000 mg/kg) or SRT1720 (100 mg/kg) was 
significantly reduced (*p < 0.05) as compared to vehicle treated control DIO mice. Error bars represent standard error of the 
mean.BMC Systems Biology 2009, 3:31 http://www.biomedcentral.com/1752-0509/3/31
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increased transcriptional activities in the SRT501 dataset
comparison with 50, 39, 6 and 11 supporting state
changes respectively (Figures 2[b] and 3[a]). Ppargc1α,
Pparα and Pparγ also have reported roles in transcrip-
tional regulation of mitochondrial biogenesis [35-37].
The increased metabolism and mitochondrial biogenesis
network in Figure 3[a] also includes increased transcrip-
tional activity of Esrrα which can upregulate mitochon-
drial respiration genes [38,39]. Finally, Nrip1 (RIP140) is
a known transcriptional repressor of genes involved mito-
chondrial biogenesis and a corepressor of Esrrα and
Pparα, and the reduced transcriptional activity of Nrip1
hypothesis is supported by 13 state changes (for a
review[40]).
To determine if the hypotheses underlying the increased
metabolism and mitochondrial biogenesis network are
supported in the SRT1720 dataset comparison, we exam-
ined the probe sets for the state changes supporting the
increased transcriptional activity of Pparα (taof(Pparα))
and increased transcriptional  activity  of  Ppargc1α
(taof(Ppargc1α)) hypotheses to determine whether their
directionality upon SRT1720 treatment was conserved.
Increased taof(Pparα) is the most statistically significant
SRT501 and SRT1720 treatment leads to increased metabolism and mitochondrial biogenesis Figure 3
SRT501 and SRT1720 treatment leads to increased metabolism and mitochondrial biogenesis. [a] Flow diagram 
of a network depicting statistically significant hypotheses supporting increased metabolism and mitochondrial biogenesis in DIO 
mouse livers after 3 days of treatment. Numbers in brackets indicate the number of RNA state changes supporting that 
hypothesis. taof – transcriptional activity of a given protein. [b] Scatter plot obtained by graphing fold changes of significant 
probe sets supporting the increased taof(Pparα) hypothesis in the SRT1720 dataset comparison versus the SRT501 dataset 
comparison. [c] Scatter plot obtained by graphing fold changes of significant probe sets supporting the increased 
taof(Ppargc1α) hypothesis in the SRT1720 dataset comparison versus the SRT501 dataset comparison. [d] C2C12 myotubes 
were treated with vehicle, SRT501 or SRT1720 at the indicated concentrations for 48 hours. Citrate Synthase activity was 
measured in lysates as a marker for mitochondrial function. p values were measured using an unpaired, 2-tailed t test. n = 3 
replicates per group for compound treatments and n = 6 replicates for vehicle treatment. Error bars represent standard error 
of the mean. (**p < 0.01, ***p < 0.001). [e] NCI-H358 cells were treated with vehicle, SRT501 (50 μM) or SRT1720 (1 μM) for 
48 hours. Cellular ATP levels were then measured as marker for mitochondrial function. P values were measured using an 
unpaired, 2-tailed t test. n = 3 replicates per group. Error bars represent standard error of the mean (*p < 0.005).BMC Systems Biology 2009, 3:31 http://www.biomedcentral.com/1752-0509/3/31
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hypothesis in Figure 3[a], supported by 50 state changes
and all 75 probe sets mapping to these 50 state changes in
the SRT501 dataset comparison are modulated in the
same direction after SRT1720 treatment (p < 10-5, Figure
3[b]). Similarly, for the 6 state changes supporting
increased taof(Ppargc1α) in the SRT501 dataset compari-
son, we determined that all 16 probes mapping to these
state changes were modulated in the same direction after
SRT1720 treatment (p < 10-5, Figure 3[c]). Finally, we
observed conserved directionality between the SRT1720
and SRT501 dataset comparisons for the state changes
supporting increased taof(Pparγ), increased taof(Pparδ),
increased taof(Esrrα) and decreased taof(Nrip1) (see
Additional file 2). Taken together these data suggest that
SRT1720, like SRT501, increases transcriptional activities
of Ppargc1α and the other Ppar family members. Ulti-
mately, these molecular signaling events contribute, at
least in part, to efficacy of SRT501 and SRT1720 in
improving glucose homeostasis and insulin sensitivity in
animal models of T2DM (Figure 2[d]).
Although, Figure 3[a] predicts activation of Ppar family
members as a molecular signaling component down-
stream of SIRT1 activation, neither SRT501 nor SRT1720
recapitulates key pharmacological activities of known
Ppar agonists, fibrates (Ppara) and thiazolidinediones
(Pparg). In animals dosed with SRT501 or SRT1720, there
were no increases in molecular markers of peroxisomes in
liver nor were there increases in liver mass (data not
shown), as one would observe in animals treated with the
fibrate class of drugs. There also were no observed side-
effects indicative of thiazolidinedione treatment, such as
edema, increased adipocyte proliferation and increased
body weight (data not shown). Thus, while small mole-
cule activation of SIRT1 impinges on Ppar activation at the
molecular signaling level, SRT501 and SRT1720 are phar-
macologically distinct from both fibrates and thiazolidin-
ediones.
In order to further validate the predicted increase in mito-
chondrial biogenesis upon SRT501 treatment, which is
also activated in response to SRT1720 treatment, we per-
formed a number of in vitro and in vivo studies. It has been
previously shown that resveratrol [31] and SRT1720 [32]
increases citrate synthase activity, an enzymatic marker for
mitochondrial content, in skeletal muscle of mice treated
with these compounds. To demonstrate that these SIRT1
activators can directly increase mitochondrial content in a
cell based model, we measured CS activity in C2C12 myo-
tubes treated with vehicle, SRT501 or SRT1720 for 48
hours. As shown in Figure 3[d], both SRT501 (12.5 and 25
μM) and SRT1720 (2.5 μM) induced statistically signifi-
cant increases in CS activity, suggesting increased mito-
chondrial content in these cells. Finally, we measured
ATP, an indirect marker for mitochondrial energy output,
in NCI-H358 cells treated with SRT501 (50 μM) or
SRT1720 (1 μM) for 48 hours. Figure 3[a] demonstrates
that both SRT501 and SRT1720 increase ATP levels with
statistical significance compared to vehicle. In conclusion,
these data, combined with previous reports on resveratrol
and SRT1720, strongly support the network shown in Fig-
ure 3[a], in which small molecule activators of SIRT1
increase mitochondrial biogenesis.
SRT501 and SRT1720 blunt inflammatory signaling 
pathways
Another well characterized hallmark of CR is decreased
inflammation [3,41-45]. Tnfα and Egf are known induc-
ers of NF-κB complex transcriptional activity, and Nr3c1
(GR) represses NF-κB complex-induced transcription by a
direct binding event as well through indirect mechanisms
such as transactivation of the IκB gene (reviewed in[46]).
Reverse causal analysis identified these inflammatory
mediators as statistically significant hypotheses after
SRT501 treatment. Figure 4[a] depicts the decreased
inflammation network with the following support:
decreased Tnfα protein abundance (supported by 28 state
changes), decreased Egf protein abundance (supported by
9 state changes), decreased transcriptional activity of the
NF-κB complex (supported by 16 state changes) and
increased transcriptional activity of Nr3c1 (supported by
14 state changes). In this model, decreased NF-κB com-
plex transcriptional activity is supported by decreased
Tnfα and Egf abundance, as well as increased Nr3c1 activ-
ity. In order to determine whether the state changes con-
sistent with decreased inflammatory signaling were
observed in the SRT1720 dataset comparison, we exam-
ined the 27 probe sets that map to the 16 state changes
supporting the decreased taof(NF-κB complex) hypothe-
sis and determined that 25 of 27 probe sets were modu-
lated in the same direction between the SRT501 and
SRT1720 dataset comparisons (p < 10-5, Figure 4[b]). Sim-
ilar analyses were performed for the other three hypothe-
ses in Figure 4[a] (decreased Tnfα, decreased Egf and
increased taof(Nr3c1), supplementary data), and it was
determined that in each case, the underlying changes in
gene expression were consistently modulated in the same
direction.
Next, we examined whether SRT501 and SRT1720 could
affect inflammatory signaling in an in vitro cell based
model, LPS-induced TNFα secretion in RAW264.7 macro-
phages. Cells were pre-incubated with compounds at the
indicated doses for 1 hour and then were treated with 100
ng/ml LPS for an additional hour. TNFα concentrations in
cell supernatants were then measured by ELISA. Figure
4[c] shows that SRT501 (20 μM) and SRT1720 (2 μM)
inhibit TNFα secretion by ~50% and ~40% respectively.
Taken together, these findings support the hypothesis that
SRT501 and SRT1720 inhibit inflammation and are con-BMC Systems Biology 2009, 3:31 http://www.biomedcentral.com/1752-0509/3/31
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sistent with prior reports suggesting that SIRT1 may
inhibit inflammatory signaling pathways [47-52].
Discussion
We have previously described the identification and char-
acterization of small molecule activators of SIRT1. These
compounds increase SIRT1 enzymatic activity by lowering
the Km of SIRT1 for its acetylated substrates. Importantly,
these drug-like molecules are efficacious in improving
glucose and insulin homeostasis in multiple animal mod-
els of insulin resistance and T2DM [31,32]. In the present
study, we characterize the early molecular signaling mech-
anisms potentially underlying the therapeutic efficacy of
SIRT1 activation by small molecules in a diet induced
obesity model. To this end we employed a combination of
Causal Network Modeling of transcriptional profiling
data and supporting in vivo and in vitro data.
Reverse causal analysis identified CR as a statistically sig-
nificant hypothesis in the SRT501 dataset comparison. To
determine whether this hypothesis is also supported in
the SRT1720 dataset comparison, we analyzed the under-
SRT501 and SRT1720 treatment leads to decreased inflammatory signaling Figure 4
SRT501 and SRT1720 treatment leads to decreased inflammatory signaling. [a] Flow diagram of a network depict-
ing statistically significant hypotheses supporting decreased pro-inflammatory signaling in DIO mouse livers after 3 days of 
treatment. Protein names lacking the taof prefix indicate decreased abundance, e.g. decreased abundance of Tnfα ligand leads 
to decreased taof(NF-κB complex). [b] Scatter plot obtained by graphing fold changes of significant probe sets supporting the 
decreased taof(NF-κB complex) hypothesis in the SRT1720 dataset comparison versus the SRT501 dataset comparison. [c] 
RAW 264.7 macrophages were treated with vehicle (0.2% DMSO), SRT501 (10 and 20 μM) or SRT1720 (1 and 2 μM) for 1 
hour. Subsequently, TNFα secretion was induced by addition of LPS at 100 ng/ml for 1 hour. Cell Supernatants were collected 
and TNFα levels were measured by ELISA. TNFα levels are depicted as a percent of vehicle control (P.O.C.). P values were 
measured using an unpaired, 2-tailed t test. n = 3 replicates per group for each compound treatment. n = 8 replicates per 
group for each vehicle treatment. Error bars represent standard error of the mean. (*p < 0.05, **p < 0.005).BMC Systems Biology 2009, 3:31 http://www.biomedcentral.com/1752-0509/3/31
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lying state changes at the probe set level. In doing so we
determined that all 73 probe sets covering 54 changes in
gene expression displayed conserved directionality
between the two dataset comparisons (p < 10-5). Hence,
these two chemically distinct small molecule activators of
SIRT1 recapitulate many of the molecular events of calorie
restriction  in vivo and importantly work via the same
molecular mechanism in vivo – SIRT1 activation, a conclu-
sion which is supported previous studies which have
shown that SRT501-resveratrol and SRT1720 increase the
deacetylation of SIRT1 substrates (e.g. p53, Ppargc1a, and
Foxo1a) in vivo and in vitro. Additionally, previous studies
have demonstrated that SRT501[30,31,53] and
SRT1720[32,54], like calorie restriction [4,8], enhance
oxidative metabolism, protect against diet induced obes-
ity, increase exercise endurance, and improve glucose and
insulin homeostasis in rodent models of metabolic dis-
ease. These findings are consistent with the role of SIRT1
downstream of calorie restriction, which, as a therapeutic
strategy, has proven efficacious in improving the meta-
bolic profiles in rodents, large mammals, monkeys and
humans [3-5,55].
Reverse causal analysis also identified increased metabo-
lism, mediated primarily by transcriptional activation of
Ppar family members, as a network supported by six statis-
tically significant hypotheses in the SRT501 dataset com-
parison. Furthermore, we determined that the changes in
gene expression which support these hypotheses are mod-
ulated in the same direction in the SRT501 and SRT1720
treatment groups. Ppar-mediated signaling is a well docu-
mented molecular event downstream of calorie restriction
[56,57]. These nuclear hormone receptors regulate a multi-
tude of physiological pathways including lipid metabo-
lism, glucose homeostasis, inflammation and development
[37,58-60]. Notably, PPARα and PPARγ are respectively the
molecular targets of the fibrate and thiazolidinedione
(TZD) classes of drugs [61,62]. Fibrates are commonly used
for therapeutic intervention of hypertension, atherosclero-
sis, and dyslipidemia. TZDs, on-the-other-hand, are insu-
lin-sensitizing reagents frequently used in the treatment of
T2DM and Metabolic Syndrome. It is important to note
that, while reverse causal analysis identified Ppar activation
as a hypothesis downstream of small molecule activation
of SIRT1, we did not observe the full range of pharmacolog-
ical effects associated with fibrate or TZD treatment, such as
increased peroxisome mass, body weight gain, increased
adipocyte proliferation and edema. We speculate that the
levels of Ppar activation and/or the subset of upregulated
Ppara gene-targets generated by treatment with SRT501 or
SRT1720 are likely more consistent with those observed
downstream of calorie restriction.
The exact mechanism by which SRT501 and SRT1720
increase transcriptional activation of Ppars is an area for
future investigation. However, it is likely due, at least in
part, to deacetylation and transcriptional activation of
Ppargc1α, a phenomenon supported by transcriptional
data in this study. Ppargc1α has been well characterized as
a co-activator for numerous nuclear hormone receptors
including Ppars [36]. Also, Ppargc1α is known to be
deacetylated at multiple lysine residues by SIRT1, leading
to increased Ppargc1α transcriptional activity [19].
Importantly, the effect of SIRT1 activation on Ppar activity
is likely tissue-specific and family member-specific. For
example, previous work in rodents has demonstrated that
SIRT1 represses Pparγ mediated transcription, leading to
increased fat mobilization and inhibition of adipogenesis
[63]. Future studies may elucidate whether Ppar activation
in tissues other than liver is important for the efficacy of
SIRT1 activating compounds and what the relative contri-
bution of specific Ppar family members is in a tissue-spe-
cific context.
Closely linked to the increased metabolism and Ppar fam-
ily activity is increased mitochondrial biogenesis, a phe-
nomenon strongly associated with CR [64]. The key node
of this network is transcriptional activation of Ppargc1α,
which, as mentioned previously, is deacetylated by SIRT1,
leading to increased transcriptional activity of Ppargc1α
[19]. This network is also supported by the increased tran-
scriptional activities of Pparα, Pparγ and Essrα and by
decreased transcriptional activity of Nrip1. Pparα, Pparγ
and Essrα can be coactivated by Ppargc1α, leading to
increased expression of target genes, many of which are
involved in mitochondrial respiration and biogenesis
[37,65]. Conversely, Nrip1 (RIP140) acts a transcriptional
co-repressor of several nuclear hormone receptors, includ-
ing Esrrα, leading to decreased expression of genes
involved in oxidative metabolism and mitochondrial bio-
genesis [40].
Within the context of the liver, the increased mitochon-
drial biogenesis may contribute to an improved metabolic
profile via increased efficiency in fatty acid oxidation and
lowering of serum triglycerides, both of which have been
shown to improve insulin sensitivity in peripheral tissues
[66]. Furthermore, it is certainly plausible that increased
mitochondrial biogenesis in other tissues, such as skeletal
muscle and adipose tissue, also contributes to therapeutic
efficacy of SIRT1 activating compounds. In fact, previous
reports have indicated that both resveratrol and SRT1720
increase mitochondrial function in skeletal muscle
[31,32]. This increase in mitochondrial capacity allows for
efficient substrate switching between lipids, during times
of fasting, and carbohydrates in response to insulin
[67,68]. Moreover, mitochondrial oxidative capacity in
skeletal muscle has been shown to be a strong predictor of
insulin sensitivity in humans [69].BMC Systems Biology 2009, 3:31 http://www.biomedcentral.com/1752-0509/3/31
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Finally, SRT501 and SRT1720 mimic calorie restriction as
demonstrated by the hypotheses consistent with
decreased inflammation. As previously mentioned, calo-
rie restriction is well known to inhibit inflammatory proc-
esses. This hypothesis is based upon decreases in signaling
of Tnfα, Egf and NF-κB complex and upon increased tran-
scriptional activity of the glucocorticoid receptor, Nr3c1.
Tnfα is a well characterized inflammatory cytokine and
has been implicated in the pathogenesis of numerous dis-
eases, including autoimmune disorders, cancer, insulin
resistance and Metabolic Syndrome [70-72]. Similarly, the
NF-κB complex, which lies downstream of the Tnfα sign-
aling cascade, is a transcriptional complex, which regu-
lates the transcription of wide variety of target genes
including inflammatory signaling factors, such as Tnfα
[73]. Egf also has an established role in inflammatory sig-
naling, most notably implicated as a fibrogenic factor
underlying the pathogenesis of COPD, cystic fibrosis and
cardiovascular disease [74,75]. Finally, the glucocorticoid
receptor Nr3c1 is a central regulator of inflammatory
responses, capable of transcriptionally repressing pro-
inflammatory genes and of transcriptionally activating
anti-inflammatory genes (reviewed in [76]). In summary,
the predicted decrease in inflammation is comprised of a
combination of upregulation of anti-inflammatory path-
ways and downregulation of pro-inflammatory pathways.
Elucidation of the exact mechanism by which SIRT1 acti-
vation leads to these events will be an area for future
investigation.
Notably, this network is supported by in vitro data, which
demonstrates that both SRT501 and SRT1720 induce
dose-dependent inhibition of LPS-stimulated Tnfα secre-
tion in a cultured macrophage cell line. Also, several prior
reports have implicated SIRT1 [47-49,51,77] and resvera-
trol [78-80] as negative regulators of inflammation both
in vitro and in vivo.
The decreased inflammation network supports the calorie
restriction model, as CR has been shown to inhibit
inflammation in multiple animal models, including
humans. Whether this decreased inflammation contrib-
utes to the therapeutic efficacy of our SIRT1 activating
compounds remains under investigation. Certainly, there
is increasing evidence that the development of insulin
resistance in obese individuals involves paracrine inter-
play between white adipose tissue and infiltrating macro-
phages. At the molecular level, this pathogenic
progression is characterized by an increase in secretion of
inflammatory cytokines, such as TNFα, IL-6 and MCP-1,
and a decrease of anti-inflammatory adipokines, such as
adiponectin (reviewed in[81]). Exacerbation of this path-
ogenic inflammatory response to include tissues such as
the liver and vasculature can ultimately contribute to the
onset of T2DM and/or Metabolic Syndrome. It has been
reported that the anti-inflammatory effects of TZDs, medi-
ated through PPARγ, are essential for the therapeutic effi-
cacy of that drug class in treating T2DM [81]. Hence, it is
quite plausible that SIRT1 activating compounds improve
glucose and insulin homeostasis, in part, by inhibiting
inflammatory signaling.
Conclusion
In conclusion, our modeling effort provides evidence that
SIRT1 activating compounds mimic many of the benefits
of calorie restriction in vivo. These compounds increase
metabolism and mitochondrial biogenesis, primarily
through transcriptional activation of Ppargc1α and Ppar
family members. Additionally, these molecules decrease
inflammatory signaling, which could theoretically
improve cytokine and adipokine profiles and reduce mac-
rophage burden in key target tissues. The total effect of
such phenomena could result in increased insulin sensi-
tivity in multiple tissues, including liver, muscle and fat.
Additionally, these compounds enhance glucose homeos-
tasis and abrogate the diabetic phenotype in multiple ani-
mal models of T2DM. Although calorie restriction has
been characterized as an effective strategy in the treatment
of diseases of aging, such as T2DM, it is logistically very
difficult to adhere to such a regimen due to the hunger
and pleasure drives for food intake. Hence, we speculate
that SIRT1 activating compounds, currently in clinical tri-
als for multiple indications, could be a promising alterna-
tive to CR in combating these diseases.
Methods
Cell culture
RAW 264.7 macrophages (ATCC #TIB-71) were main-
tained in DMEM (Invitrogen #11995) with 10% Fetal
Bovine Serum (low endotoxin; Benchmark; Gemini #100-
106). C2C12 (ATCC #CRL-1772) were maintained in
DMEM (Invitrogen #11995) with 10% Fetal Bovine
Serum (Foundation; Gemini #900-108). NCI-H358 cells
were maintained in DMEM (Invitrogen #11995) with
10% Fetal Bovine Serum (Invitrogen). All cell lines were
cultured in the presence of penicillin/streptomycin (Invit-
rogen).
ATP assay
NCI-H358 cells were plated at 104 cells per well in 96 well
plates. 16 hours after plating cells were treated with either
SRT501 (50 μM), SRT1720 (1 μM), or vehicle control
(DMSO, 0.5% final concentration). All compounds were
delivered at a final DMSO concentration of 0.5%. After 48
hours of incubation with compounds under normal
growth conditions, cells viability was assessed using
AlamarBlue™ reagent (Invitrogen). Cells were grown with
viability reagent for 2 hours under normal growth condi-
tions. AlamarBlue™ signal was measured using a Spec-
traMax M5 plate reader (Molecular Dynamics; excitationBMC Systems Biology 2009, 3:31 http://www.biomedcentral.com/1752-0509/3/31
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545 nm; emission 575 nm). Cell supernatant was then
removed and cells were washed 2 times in PBS. ATP levels
were measured using the ATPLite 1Step kit (Perkin
Elmer), following the manufacturers protocol. Biolumi-
nescence was measured using a SpectraMax M5 plate
reader.
Citrate synthase assay
Citrate Synthase enzymatic activity was measured using a
modified version of the protocol described by Moyes,
1997[82]. C2C12 were seeded in 96 well plates and grown
to confluence. Subsequently, cell media was changed to
differention media: DMEM (Invitrogen #11995) contain-
ing 2% Horse serum (Hyclone #SH30074.02) and peni-
cillin/streptomycin (Invitrogen). After two days of
differentiation, cells were treated with fresh differentia-
tion media containing containing one of the following,
SRT501 (12.5 or 25.0 μM), SRT1720 (1.25 or 2.50 μM), or
vehicle control (DMSO, 0.5% final concentration). All
compounds were delivered at a final DMSO concentration
of 0.5%. After 48 hours of incubation with compounds
under differentiation conditions, media was then
removed and cells were washed 2 times in PBS. Cells were
lysed for 15 minutes at 4°C, using an addition of 90 μl of
Cell Lytic M® (Sigma) to each well. Next, 100 μl of 2×
Reaction Buffer (0.1 M Tris HCl pH 8.0, 0.2 mM 5,5'-
dithio-bis(2-nitrobenzoic acid), 0.6 mM Acetyl Coen-
zyme A) was added to each well. Citrate Synthase reaction
were initiated by addition of 10 μl of 10 mM oxaloacetate
to well. Final concentrations of reaction mixture compo-
nents were 50 mM Tris HCl pH 8.0, 0.1 mM 5,5'-dithio-
bis(2-nitrobenzoic acid), 0.3 mM Acetyl Coenzyme A,
and 0.5 mM oxaloacetate. After addition of oxaloacetate,
plates were shaken for 30 seconds and then read, using a
SpectraMax M5 plate reader (Absorbance 412 nm).
Absorbance readings were taken every 30 seconds for 15
minutes. Raw Citrate Synthase activity was expressed as
the slope of the linear regression plot of the change in Abs
412 nm over time. Cell viability was measured as
described for ATP Assay.
TNF  secretion assay
RAW 264.7 macrophages were seeded at 4 × 104 cells per
well in 96 well plates. 16 hours after seeding cells were
treated with either SRT501 (10 or 20 μM), SRT1720 (1 or
2 μM), or vehicle (DMSO; 0.2% final concentration). All
compounds were delivered at a final DMSO concentration
of 0.2%. After 1 hour of incubation with compound
under normal growth conditions, 100 ng/ml (final con-
centration) of lippopolysaccharide (E. coli; Calbiochem)
or vehicle control (water) was added to each well. Follow-
ing 1 hour of incubation with LPS (to stimulate TNFα
secretion), cell supernatants were removed from each well
and transferred to TNFα ELISA plates (mouse-specific,
Invitrogen). TNFα levels were measured according to the
manufacturer's protocol. ELISA signal was measured by
reading Absorbance at 450 nm using a SpectraMax M5
plate reader. Cell viability was measured as described for
ATP Assay.
Diet induced obesity model
This study was approved by the Institutional Animal Care
and Use Committee (IACUC) of Enanta (Watertown, MA)
(Protocol # 2005-17), and carried out in accordance with
federal (USA) IACUC regulations.
Nine week old C57BL/6 male mice (Charles River Labs)
were fed a high fat diet (60% calories from fat; Research
Diets) until their mean body weight reached approxi-
mately 40 g. The mice were then divided into test groups
(6-10 per group). SRT1720 (100 mg/kg) and SRT501 (500
mg/kg) were administered once daily via oral gavage. The
vehicle used was 2% HPMC + 0.2% DOSS. Individual
mouse body weights were measured twice weekly. Fasted
blood glucose was measured after 3 weeks of dosing with
compounds. To obtain fasting blood glucose measure-
ments, food was removed late in the day (4 PM) before
the glucose reading was taken the following morning.
Fed Insulin levels were measured from plasma after 4
weeks of dosing with SRT501 or vehicle and after 6 weeks
of dosing with SRT1720 or vehicle. Blood insulin levels
were measured from Linco EZ-RMI13K. To obtain fed
insulin measurements, food was removed one hour
before the blood collection.
Transcriptional profiling
Livers were harvested after 3 days of dosing (1–2 hours
after the third dose) with compounds or control (4 mice
per group). Livers were snap-frozen on liquid nitrogen
and shipped to Expression Analysis, Inc. (Durham, NC)
for RNA preparation and transcriptional profiling. RNA
was purified using the RNeasy Mini Kit (QIAGEN) accord-
ing to the manufacturer's procedure, including the on-col-
umn DNase I digestion. For expression profiling, 2 μg of
total RNA was converted to double stranded cDNA using
the One-Cycle cDNA Synthesis Kit from Affymetrix (Part
Number 900431) and in vitro transcribed using the IVT
Labeling Kit from Affymetrix (Part Number 900449)
according to Expression Analysis' standard operating pro-
cedures. Biotin-labeled cRNA at a final concentration of
50 ng/μl was hybridized to Mouse Genome 430 2.0 Arrays
according to the manufacturer's procedure.
Selection of molecular state changes for analysis
RNA expression data were generated using Affymetrix
Mouse Genome 430 2.0 expression microarrays and ana-
lyzed using the "affy" and "limma" packages of the Bio-
conductor suite of microarray analysis tools available for
the R statistical environment [83-86]. RMA backgroundBMC Systems Biology 2009, 3:31 http://www.biomedcentral.com/1752-0509/3/31
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correction and quantile normalization was used to gener-
ate microarray expression values. An overall linear model
was fit to the data for all sample groups and specific con-
trasts of interest were evaluated to generate raw p-values
for each probe set on the expression array [87]. The Ben-
jamini-Hochberg FDR method was then used to correct
for multiple testing effects. Probe sets were considered to
have changed qualitatively in a specific comparison if an
adjusted P-value of 0.05 was obtained, both their average
expression intensity was above 250 and they had a fold
change greater than 1.3. Alternatively, if the average inten-
sity in each dataset was below 250 but they had a fold
change greater than 1.5 and were present by Affymetrix
absence/presence calls in one of the datasets, probe sets
were also considered changed. Genes represented by mul-
tiple probe sets were considered to have changed if at least
one probe set was observed to change. Expression changes
that met these criteria are called statistically significant
"RNA state changes" and have the directional qualities of
"up" or "down", i.e., they can be upregulated or downreg-
ulated in response to compound treatment.
Knowledgebase and mouse knowledge assembly model
The substrate for analysis of RNA state changes observed
in the SRT501 dataset comparison is the mouse knowl-
edge assembly model, which is derived from a global Gen-
struct knowledgebase. This knowledgebase is a collection
of biological concepts and entities and their causal rela-
tionships and is derived from peer-reviewed scientific lit-
erature as well as other public and proprietary databases
and has been constructed during the course of projects in
areas such as inflammation, metabolic diseases, cardio-
vascular injury, liver injury and cancer. The mouse knowl-
edge assembly model is the set of mouse-specific causal
assertions that has been augmented with orthologous
causal assertions derived from either rat or human sources
and is competent for reverse causal analysis. An example
causal assertion would be increased transcriptional activ-
ity of NF-κB complex causing an increase in the expression
of insulin response factor 1(Irf1) [88]. Each such causal
assertion has a specific scientific citation, and the assem-
bled collection of these causal assertions is referred to as
the mouse knowledge assembly model in this paper.
Reverse causal analysis: automated hypothesis generation
In the case of RNA expression data, Causal Network Mod-
eling employs an automated reverse causal analysis
approach which interrogates the mouse knowledge
assembly model to identify upstream controllers for the
RNA state changes observed in the experiment. These
upstream controllers are called hypotheses as they are sta-
tistically significant potential explanations of the RNA
state changes. Hypothesis generation is performed auto-
matically by a computer program that utilizes the mouse
knowledge assembly model to identify hypotheses that
explain the input RNA state changes, prioritized by multi-
ple statistical criteria. Each hypothesis is scored according
to two probabilistic scoring metrics, richness and con-
cordance, which examine distinct aspects of the probabil-
ity of a hypothetical cause explaining a given number of
RNA state changes. Richness is the probability that the
number of observed RNA state changes connected to a
given hypothesis could have occurred by chance alone.
Concordance is the probability that the number of
observed RNA state changes that match the directionality
of the hypothesis (e.g., increased or decreased kinase
activity for a kinase, increased or decreased transcriptional
activity for a transcription factor, etc.) could have occurred
by chance alone. A hypothesis is considered to be statisti-
cally (although not necessarily biologically) significant if
it met richness and concordance cutoffs of 0.1. The statis-
tical threshold of 0.1 has been determined as an appropri-
ate cutoff to begin building networks; known biology
downstream of a given perturbation has been appropri-
ately modeled using these thresholds. Automated reverse
causal analysis on the SRT501 dataset comparison yielded
146 statistically significant hypotheses, which were fur-
ther investigated and prioritized by evaluation of their
biological relevance to the experimental context, whether
they are causally linked to phenotypes and processes rele-
vant to known sirtuin function in the literature and if they
are causally downstream of Sirt1 activation. To build net-
works, core hypotheses which are strongly statistically sig-
nificant (< 0.05) are first identified, then other hypotheses
which fall in the 0.05 to 0.1 range are used as additional
support. Using both the information stored in the mouse
knowledge assembly model and from literature investiga-
tion, causal links between selected hypotheses were iden-
tified enabling incorporation into an overall biological
network capable of explaining the effects of SRT501 treat-
ment, called the Causal Network Model (CNM). Out of
the 146 hypotheses identified by reverse causal analysis,
twelve hypotheses make up the three pathways described
in the manuscript. These pathways were chosen because
to date, they have been validated by in vitro and in vitro
experimental data.
Comparing the SRT501 causal network model to the 
SRT1720 dataset comparison
In order to compare the hypotheses identified based on
SRT501 treatment to the SRT1720 dataset comparison, we
compared the directionality of the RNA state changes sup-
porting statistically significant hypotheses in the SRT501
dataset comparison to those in the SRT1720 dataset com-
parison on the probe set level. The number of probe sets
with fold changes in the same direction in the SRT501 and
SRT1720 dataset comparisons was determined for each of
the twelve hypotheses discussed in this paper. P-values
were calculated based on binomial distribution assuming
no relationship between the SRT501 and SRT1720 datasetBMC Systems Biology 2009, 3:31 http://www.biomedcentral.com/1752-0509/3/31
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comparisons. This method allowed us to detect whether
general trends in the directionality of the RNA state
changes supporting hypotheses identified based on
SRT501 treatment were also present after SRT1720 treat-
ment.
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